Prostate Cancer International is
for 2011 by Great NonProfits
According to a corporate media release, issued yesterday, Gen-Probe has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) seeking approval to market the company’s version of the PCA3 test, known as Progensa®.
Filed under: Diagnosis, Risk | Tagged: assay, Diagnosis, PCA3, Progensa, risk, test | 3 Comments »
An editorial commentary printed in today’s New York Times is focused on an estimate by the US Congressional Budget Office that “an astonishing half or more of the increased spending for health care in recent decades is due to technological, surgical and clinical advances.”
Filed under: Diagnosis, Risk | Tagged: Diagnosis, outcome, PSA, risk, screening, test | 3 Comments »
Over the past few months, the US Food and Drug Administration (FDA) has issued a slew of letters to companies marketing tests designed to provide consumers with information about their genetic profile and their risks for certain types of disease.
Filed under: Diagnosis, Risk | Tagged: genes, genetics, risk, test | 4 Comments »
A media release from the Uniformed Services University of the Health Sciences last week announced the development of a highly specific assay for the detection of ERG oncoprotein. The assay is based on the development of an anti-ERG monoclonal antibody that appears to be capable of detecting the presence of ERG oncoprotein with > 99 percent accuracy.
Filed under: Uncategorized | Tagged: ERG, monoclonal antibody, oncoprotein, test | Leave a Comment »
Data just published in Nature Biotechnology suggests that a new type of PSA test developed by a company called Quanterix is 1,700 times more sensitive than older, standard PSA detection methods used in clinical laboratories.
Filed under: Living with Prostate Cancer, Management, Risk | Tagged: PSA, Quanterix, sensitive, test | 3 Comments »
Men with prostate cancer who are 70 years of age or older, and who are starting adjuvant androgen deprivation therapy (ADT) for locally advanced or high-risk localized prostate cancer, should receive a bone mineral density (BMD) test followed by selective bisphosphonate therapy for those with osteoporosis, according to an article in today’s issue of Annals [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, alendronate, androgen deprivation therapy, bisphosphonate, BMD, bone mineral density, test | Leave a Comment »
Based on data from a study published recently in the British Journal of Cancer, media reports have suggested that men in the UK who undergo testing to detect prostate cancer suffer from significant psychological stress.
Filed under: Diagnosis, Risk | Tagged: biopsy, distress, PSA, stress, test | 2 Comments »
The “New” Prostate Cancer InfoLink has long taken the position defined by the Iowa Consensus, that PSA testing in men aged 75 and older should be based on the health characteristics and life expectancy of individual patients, as compared to an arbitrary cut-off of PSA testing in all men at age 75 years.
Filed under: Diagnosis, Risk | Tagged: > 75 years, age, PSA, test | 5 Comments »
In a case that has major ramifications for the health care industry and for personalized medicine, a federal judge in New York yesterday invalidated the patents on BRAC1 and BRAC2 genes held by Myriad Genetics and the University of Utah.
Filed under: Diagnosis, Management, Prevention, Risk, Treatment | Tagged: gene, patent, test | 1 Comment »
A new mini-review article in BJU International provides additional insights into the potential uses of the PCA3 test in clinical practice.
Filed under: Diagnosis, Management, Risk | Tagged: PCA3, prostate cancer gene 3, test | 3 Comments »
In what may become one of the landmark patent lawsuits of the 21st Century, a consortium of patients, pathologists, and researchers, with the support of the American Civil Liberties Union (the ACLU), has filed a lawsuit against Myriad Genetics and the U.S. Patent Office. They are challenging the right of the Patent Office to grant [...]
Filed under: Diagnosis, Risk | Tagged: gene, patent law, test | Leave a Comment »
A report from the British Broadcasting Corporation this morning says, “Scientists found that in patients with prostate cancer exosomes contain molecules that come directly from the tumour itself.” These particular “exosomes” are fatty capsules that are flushed out of the body in the urine.
Filed under: Diagnosis, Risk | Tagged: exosomes, risk, test, urine | Leave a Comment »
An article in the current issue of Cancer Research discusses some work that might lead to the type of test we really need to be able to diagnose clinically significant prostate cancer at an early stage and differentiate between this type of prostate cancer and indolent disease.
Filed under: Diagnosis, Risk | Tagged: mRNA, new, SLC45A3-ELK4, test | 1 Comment »
In today’s prostate cancer news update we report on: Awareness of the PSA test in men with other recognized health risks A new urine test that may differentiate between prostate cancer and BPH Markers for the likelihood of effectiveness of androgen deprivation from an ongoing Finnish multicenter trial
Filed under: Diagnosis, Prevention | Tagged: awareness, cancer, diagnostic, news, PHP94, prostate, PSA, risk, test, update | Leave a Comment »
Health Discovery Corporation (HDC) has announced the successful completion of a double-blind, Phase III trial of its new gene-based molecular diagnostic test for prostate cancer.
Filed under: Diagnosis | Tagged: cancer, diagnostic, gene-based, news, prostate, test, update | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site